KRAS and non-small cell lung carcinoma: A separate ongoing open label phase II study (NCT01229150) that uses selumetinib in the second line setting is randomizing patients after testing for the presence of KRAS mutations; those with KRAS wild-type NSCLC will be randomized to receive erlotinib vs. erlotinib plus selumetinib, whereas the patients with KRAS mutations are randomized into a selumetinib vs. a selumetinib plus erlotinib group.